Treatment of cancer patients with a low-density-lipoprotein delivery vehicle containing a cytotoxic drug.
A cytotoxic drug (vincristine, VC) was incorporated into low-density lipoprotein (LDL) and given to cancer patients for the first time by repeated intravenous injection. Individuals presenting with ovarian or endometrial cancer received four or five weekly doses of 1.4 mg/m2 LDL/VC. The uptake of LDL/VC by the adrenal cortex and the liver was minimised by concurrent administration of prednisolone and chenodeoxycholic acid. No febrile, allergic or other reaction attributable to the LDL occurred, and no side effect on haemopoietic, adrenal or liver functions was observed. The neurotoxic side effects commonly seen during VC therapy appeared to be reduced. These results suggest that directed cytotoxic therapy might be achieved in humans through the use of LDL as a carrier. Thus, dose-range and comparative studies using LDL/VC vs VCSO4 are warranted in malignancies in which treatment with the latter drug has been established.
Filipowska
D
D
Oncology Hospital, Bialystok, Poland.
Filipowski
T
T
Morelowska
B
B
Kazanowska
W
W
Laudanski
T
T
Lapinjoki
S
S
Akerlund
M
M
Breeze
A
A
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy*; D000302:Adrenal Cortex / Q000187:drug effects; D002635:Chenodeoxycholic Acid / Q000008:administration & dosage; D003536:Cystadenocarcinoma / Q000097:blood / Q000188:drug therapy*; D004337:Drug Carriers; D004359:Drug Therapy, Combination; D016889:Endometrial Neoplasms / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL; D008099:Liver / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood
D004337:Drug Carriers; D008077:Lipoproteins, LDL; D002635:Chenodeoxycholic Acid; D014750:Vincristine; D011239:Prednisolone